Connect with us
White Bridge Investments currently holds 70% of the shares of Biofarma Group, while the remaining 30% belongs to Germano Scarpa and Gabriella Tavasani. White Bridge had...
Peptomyc has focused its project on the development of a new generation of cell-penetrating peptides (CPP) targeting the Myc oncoprotein, with the aim of treating different...
Qmenta needs $10 million to further expand. For the time being, the company's main front will remain neurological diseases. Currently, one billion people worldwide suffer from...
The blood-brain barrier is a major hurdle in treating a whole range of diseases affecting the CNS. While it serves a vital role in protecting against...
Stocks like BB Biotech should be treated with caution. Nevertheless, there is a quite realistic chance that investors will receive a higher dividend from BB Biotech....
Estimated as a $3 billion opportunity for Bioasis Technologies, the company's xB3 platform is set to revolutionize the treatment of neurological disease. The technology helps deliver...
Aortyx has received a $2.8 million (€2.5 million) grant from the European Commission. Prior to this investment, the company was already recognized and funded with more...
The negative variation of the Spanish pharmaceutical sector contrasts with the positive performance of the Ibex35, which recorded a rise of 8% at the close of...
The Spanish multinational Grifols, specialized in the production of blood products, has continued to expand its network with the launch of the first integrated plasma supply...
Moira Capital, based in Madrid, started its activity in early 2017 as a manager specialized in direct high-return investments for private investors and institutions. The company...
 |
|
 |  |
 |
|